Hi [[ session.user.profile.firstName ]]

Medical Research

  • Introducing the CellStreamTM System, A Highly-Sensitive, 7-Laser Flow Cytometer
    Introducing the CellStreamTM System, A Highly-Sensitive, 7-Laser Flow Cytometer Robert Smith-Mccollum and Christine Probst Recorded: Jul 18 2018 40 mins
    MilliporeSigma is excited to launch the new CellStreamTM benchtop flow cytometry system, a highly-customizable, highly-sensitive 7-laser flow cytometer. Its unique optics system and design provides researchers with unparalleled sensitivity and flexibility when analyzing cells and submicron particles. Within the CellStreamTM system, the Amnis® time delay integration (TDI) and camera technology rapidly captures low resolution cell images and transforms them into high-throughput intensity data. Researchers acquire the intensity data they are accustomed to from traditional flow cytometers, but with greater fluorescence sensitivity. Join us in this webinar to take a deeper look inside the instrument design, system performance and software of this exciting new system.
  • Key components of a comprehensive program for the management of single use techn
    Key components of a comprehensive program for the management of single use techn John Maguire, Shire & Donald Young Thermo Fisher Recorded: Jul 18 2018 74 mins
    As a result of the increased adoption of single-use technologies (SUTs) in biotech manufacturing, companies need to develop and implement programmatic approaches for the management of these systems under regulatory compliance. This webinar discusses the key aspects of such programs, with emphasis on collaboration with suppliers, cost management, as well as practical insights about the use of SUTs.
  • Proficiency Testing Portal Training
    Proficiency Testing Portal Training Jennifer Duhon Recorded: Jul 12 2018 17 mins
    We have taken your feedback shared with us over the years and used this to help improve our service to you. With this new portal, you will find new features including your methods now saved as default, graphical reports, the option to trend your data, as well as the ability to expand and collapse your items on the data entry screen which will allow for quicker loading times. This presentation will go through each feature step by step. If you could like to skip straight to how to enter data, please go to slide 34.
  • How to accelerate your innovation pipeline using Social Impact Investments
    How to accelerate your innovation pipeline using Social Impact Investments Rosemarie Truman from The Center for Advancing Innovation Recorded: Jul 12 2018 45 mins
    Social Impact Investment brings together capital and experience from the public, private and non-for-profit industries to achieve specific social objectives. The return of these investments is measured typically by the social outcomes achieved.

    The Centre of Advancing Innovation is a public-private partnership non-profit focused on identifying breakthrough inventions hidden in portfolios, to maximise investor returns and commercial success. Research performed by the group has highlighted that Social Impact projects accelerate innovation, and result in higher returns.

    In this webinar, Rosemarie Truman, CEO and Founder of CAI will be discussing the positive implications of choosing social impact projects for your business, including:

    - Why they accelerate innovation
    - How these projects can increase your potential investment opportunities for the future
    - The influence on the future funding of projects.
  • Development and Manufacturing of Recombinant Nanoparticle Vaccines
    Development and Manufacturing of Recombinant Nanoparticle Vaccines Atin Tomar, President of CPL Biologicals & Amelie Boulas Of Sartorius Stedim Recorded: Jul 12 2018 67 mins
    A recombinant vaccine technology platform based on highly purified, properly-folded protein antigens in stable well-defined Nanoparticles, enabling efficient and safe manufacture of vaccines against highly pathogenic targets. Nanoparticles are intrinsically immunogenic, producing both durable neutralizing antibodies and cellular immunity. The platform can be utilized for rapid response to potential pandemics as the time from identification of relevant viral gene sequence to final GMP drug product ready for human studies has been demonstrated to take less than 4 months for multiple vaccines.
    The GMP drug substance manufacturing process for the platform largely utilizes single-use technologies. Single-use-technologies and recombinant platform enables the utilization of same manufacturing facility for multiple products with rapid change-over.
  • Object Storage. What it Solves & Why it’s Better for Your Data at Scale.
    Object Storage. What it Solves & Why it’s Better for Your Data at Scale. Mike McWhorter, Senior Technologist, Western Digital Recorded: Jul 10 2018 25 mins
    Most have heard about object storage, but what problem is it solving, and how does it compare to other storage solutions like SAN or NAS? If these are questions you’ve asked yourself this webinar is for you! (Hint: The problem Object Storage solves is scalability.)

    Join Senior Technologist Mike McWhorter as he explains how Object Storage differs from SAN, NAS and distributed file systems, the unique technological features which make object storage ideal for archiving, accessing or protecting data (especially unstructured data), and how different industries are using Object Storage today.

    Register today to watch live or for the on-demand recording.
  • Proficiency Testing Portal Training
    Proficiency Testing Portal Training Jennifer Duhon Recorded: Jul 10 2018 17 mins
    We have taken your feedback shared with us over the years and used this to help improve our service to you. With this new portal, you will find new features including your methods now saved as default, graphical reports, the option to trend your data, as well as the ability to expand and collapse your items on the data entry screen which will allow for quicker loading times. This presentation will go through each feature step by step. If you could like to skip straight to how to enter data, please go to slide 34.
  • Soft Tissue Cancer & IHC
    Soft Tissue Cancer & IHC Jeff Gordon Recorded: Jun 29 2018 65 mins
    Soft tissue tumors are a broad group of neoplasms that involve the connective tissue of the body. Each year, over 13,000 people in the US are diagnosed with soft tissue sarcomas and over 5,000 people succumb to the malignancy. Because soft tissue sarcomas are very ambiguous and amorphous, many time sarcomas are classified as an uncertain type. Advances in immunohistochemistry as well as the utility of novel markers such as TFE3, TLE1, MyoD1, and MUC4 have aided pathologists in classifying these soft tissue tumors. This discussion will cover the key facts and statistics about soft tissue tumors and what role IHC plays in these difficult diagnoses.
  • Multiplexed immunofluorescence and digital image analysis for clinical use
    Multiplexed immunofluorescence and digital image analysis for clinical use Mehrnoush Khojasteh, PhD & Lei Tang, PhD Recorded: Jun 28 2018 63 mins
    There is an ever increasing need to understand the role of the Tumor Microenvironment (TME) in Cancer Immunotherapy. In this webinar, Drs. Lei Tang, PhD and Mehrnoush Khojasteh,PhD of Roche Tissue Diagnostics (Ventana Medical Systems, Inc.), present their work on multiplex immunofluorescence staining and digital pathology analysis in a CAP/CLIA certified laboratory. Multiplexed immunohistochemistry (IHC) enables the spatial characterization of TME immune cells and tumor cells by detecting multiple biomarkers while preserving tissue morphology. Co-expression of multiple biomarkers and relative spatial relationships requires whole slide digital pathology image analysis algorithms that are tailored to individual assays and their intended uses. The process described in this presentation demonstrates how multiplexing and digital pathology enable biotech and pharmaceutical research and development teams to explore the potential medical value of specific biomarkers,
  • CRISPR Protein Products
    CRISPR Protein Products Yanfang Jiang, Ph. D. Recorded: Jun 28 2018 32 mins
    MilliporeSigma is a pioneer in commercially offering targeted genome editing tools. With its 14-year experience in the first generation of genome editing tools such as TargeTron® and Zinc Finger Nuclease, MilliporeSigma has emerged as a prominent leader in the development of CRISPR systems, the most flexible and efficient genome editing technology thus far developed. CRISPR-based DNA integration patents have been granted to MilliporSigma in seven regions including Australia, Canada, the European Union, Singapore, Israel, South Korea, and most recently in China. The MilliporeSigma CRISPR portfolio consists of an array of CRISPR products, in both the plasmid, RNA, protein, and lentiviral formats. MilliporeSigma is also the first commercial provider to offer both pooled and arrayed whole human genome CRISPR libraries.

    In this webinar, we will give an introduction to our current CRISPR protein products, including SpCas9 (CAS9PROT), Cas9-D10A nickase (CAS9D10APR), high fidelity eSpCas9 (ESPCAS9POR), catalytically inactive dCas9-FLAG-biotin (DCAS9PROT), and FnCas9 (FNCAS9PROT), focusing on specific enzyme characteristics of each protein and their potential applications for the research community.
  • Strategies to overcome Low Endotoxin Recovery using the conventional LAL assay
    Strategies to overcome Low Endotoxin Recovery using the conventional LAL assay Dr. Ruth Daniels, Janssen & Kevin L. Williams, BIOMÉRIEUX USA, Inc. Recorded: Jun 28 2018 63 mins
    Title: Strategies to overcome Low Endotoxin Recovery using the conventional LAL assay
    Presenter: Dr. Ruth Daniels, Janssen
    This presentation will discuss:
    - Endotoxin hold time studies to identify LER
    - In silico assessment of interfering factors and associated LER mitigation strategies
    - Case study: optimization of product-specific LAL assay to overcome LER

    Title: : Addressing LER at the root, with ENDO-RS® sample preparation (demasking) prior to endotoxin assay of choice
    Presenter: Kevin L. Williams, Senior Scientist Endotoxin - BIOMÉRIEUX
    Scientific studies have demonstrated that biologics typically containing protein in high concentrations and non-ionic surfactants, are likely to change the aggregate state of endotoxin in such a way that it is no longer accessible for detection with Factor C-based endotoxin detection methods (LAL and rFC). The ENDO-RS® endotoxin recovery method developed by Hyglos - a bioMérieux company, is a unique toolbox of dedicated reagents for demasking (recovering) endotoxin prior to detection, also for conventional LAL. This presentation covers the mechanism of LER, regulatory requirements, work principle of ENDO-RS, the demasking services of bioMérieux, as well as method application data.
  • Modelling Piezoelectric Devices
    Modelling Piezoelectric Devices Paul Wilson, Knowledge Transfer Associate, Queen's University Belfast and Richard Chippendale, Technical Manager, COMSOL Recorded: Jun 27 2018 49 mins
    In this webinar, learn about a multiphysics approach for modelling piezoelectric devices with couplings between electrostatics, acoustics and structural mechanics. Incorporating such models within the design process enables a better understanding of the interactions between structural materials, piezoelectric ceramics and fluid damping, which can reduce development time and prototyping costs.

    Piezoelectric transducers can be used, for example, in ultrasonic cleaning, sonochemistry and cell disruption or homogenisation. For such applications it is important to accurately design the ultrasonic horns (or sonotrodes) to increase the amplitude of piezoelectric vibrations and transfer energy to liquids through the production and disintegration of microscopic bubbles.

    In this presentation, Paul Wilson from Queen's University Belfast will discuss how to design such a horn to maximise power transfer to a liquid. An existing transducer will be modelled and the tuning of material parameters to match experimental results will be discussed. Parametric sweeps are then used to investigate the design space of the horn and predict the electrical and mechanical properties of the model. These results can then inform experimental procedure, where the simulated response shows strong agreement with laboratory measurements.

    The webinar will include a live demonstration in the COMSOL Multiphysics® software and conclude with a Q&A session.
  • Digital Therapeutics: Trends and Growth Opportunities
    Digital Therapeutics: Trends and Growth Opportunities Frost & Sullivan's Global Digital Health Team, Wolf Shlagman CEO - Care Angel, Amer Haider CEO - Doctella Recorded: Jun 26 2018 61 mins
    Digital therapeutics presents a significant opportunity for traditional pharmaceutical therapeutics and information technology (IT) capabilities to influence a new approach to increase positive patient outcomes while reducing the overall cost of healthcare.

    Key Takeaways:
    · Gain expert insight into the accurate definition of digital therapeutics and market participants.
    · Learn about new solutions from mHealth companies that will combine apps, patient education, professional intervention and peer support to increase patient engagement and medication adherence by augmenting or replacing traditional drug therapeutics.
    · Hear opportunities to utilize digital therapeutics to improve medical workflow and patient communications.
    · Learn about some of the critical milestones related to digital therapeutics.
  • IoT & A.I. For Good
    IoT & A.I. For Good Wael Elrifai, Vice President of Solution Engineering, Big Data, IoT & A.I, Hitachi Vantara Recorded: Jun 21 2018 41 mins
    Wael Elrifai shares his experience working in the IoT and AI space; covering complexities, pitfalls, and opportunities to explain why innovation isn’t just good for business—it’s a societal imperative.
  • Platform tech development for biosimilar upscaling
    Platform tech development for biosimilar upscaling Dr Hung Fai Poon, President, QuaCell Biotech Ltd and Floris De Smet, Sartorius Stedim Biotech Recorded: Jun 21 2018 68 mins
    Discover strategies to move candidate molecules through development
    Building consistent, straightforward processes with low variability
    Exploring the possibility of using single use, high throughput bioreactors in the upscaling process
  • Short Tutorial: Techniques for Harvesting Adherent Cells
    Short Tutorial: Techniques for Harvesting Adherent Cells Corning Life Sciences Recorded: Jun 18 2018 5 mins
    Harvesting your cells is an important step in maintaining healthy cultures. Good technique will lead to a healthy single cell suspension. There are many harvesting options depending on the cell line and application. In this video, we will discuss some tips/tricks to harvesting cells.
  • User Profiles Tutorial
    User Profiles Tutorial Kathleen Berryman Recorded: Jun 18 2018 4 mins
    A short tutorial showing how to create and use the user profiles feature in Cabells.
  • An Interview with Dr Günter Jagschies, of GE BioProcess teams
    An Interview with Dr Günter Jagschies, of GE BioProcess teams Interview with Dr. Günter Jagschies, business advisor for the GE BioProcess teams Recorded: Jun 18 2018 65 mins
    AN INTERVIEW WITH DR GÜNTER JAGSCHIES, OF GE BIOPROCESS TEAMS ON WHAT ARE THE MAIN OPPORTUNITIES AND CHALLENGES IN THE RAPIDLY EVOLVING ASIAN BIOPHARMA MARKETS?

    Demand for better, more precise, and effective medicines is driven by a changing global population and increased economic power in growth economies. Asia and the Sub-Saharan Africa are almost exclusively driving the global population growth. Also, the ageing populations are growing there, resulting in an increased demand on the healthcare systems. But simultaneously, there are also more and more Asian patients who can afford treatment with biologics, which is aided by generally lower price levels and improved economic situations in the region.

    Currently, the Asian biopharma industry is mainly concentrated in China, India, South Korea, Japan, and Taiwan, but the development of these markets is going to be heterogenous as they have, for example, different starting points, local policies and biopharma know-how. However, these countries are likely to face a market fragmentation challenge, because a large number of Asian companies are all focusing on the development of biosimilars for only a very few (5-10) original drugs, while at the same time many multinational companies are also entering the region. This requires more product development and manufacturing innovation from the local players to develop a differentiated position in their markets and to move to original drugs, although access to affordable biosimilars is also critical.
  • Manufacturing strategies for Biosimilar: A case of continuous capture
    Manufacturing strategies for Biosimilar: A case of continuous capture Solomon Alva, Biocon & Presented by Yvan Ruland, PhD, Technology Director, Asia/Pacific operations, Novasep Asia Recorded: Jun 15 2018 74 mins
    Presented By Solon Alva Antibody Purification Group Lead, Senior Scientific Manager, Biocon Research Limited
    Continuous manufacturing is an emerging technology in biopharmaceutical industry. The focus of this webinar is a case-study on the benefits of continuous Protein A capture on productivity, capacity utilization and buffer consumption. The potential challenges of adopting the technology such as its integration with cell culture and low pH incubation step has been discussed. There is promise of this technology as an effective platform, and potential of additional savings when considering new generation Protein A resins and in-line concentration technologies.
    Followed by Yvan Ruland, PhD, Technology Director, Asia/Pacific operations, Novasep Asia
  • Fully continuous biosimilar manufacturing framework: A case study
    Fully continuous biosimilar manufacturing framework: A case study Samir Varma, Head of Manufacturing, Enzene Biosciences and Lotta Molander, Global Product Manager, GE Healthcare Recorded: Jun 14 2018 68 mins
    Biologics manufacturing has traditionally been in fed batch mode for the last 2 decades. During the early stages of biologics manufacturing, lower cell line productivity and product instability necessitated the usage of perfusion technology. As productivity increased and mabs became more stable, perfusion was replaced by fedbatch technology, as they were simpler to scale up. However, during the past 2-3 years, the perfusion technology is making a comeback due to the novel continuous chromatography technology. Connecting the perfusion bioreactor to the continuous chromatography system creates a continuous flow of drug substance and promises the following advantages

    The facility footprint for a continuous manufacturing plant would be substantially lower. Our calculations show that a 10-fold reduction in bioreactor size is possible with continuous bioprocessing. So the capacity of a 2000L Fed batch Bioreactor can be achieved by a 200L continuous bioreactor. This reduces the capex by about five fold.
    Consumption of media per amount of DS produced is the same for fedbatch and perfusion, although the cost per liter might be lower for perfusion as it could be a more diluted version of the fedbatch media ,
    Another major cost in bioprocessing is the Protein A resin. A significantly smaller Protein A column could be used in the continuous process and the utilization could be maximized by this strategy.
    As the process is more dynamic in continuous, automation and in-line analytical tools are essential for the successful implementation.
    Enzene Biosciences is on the forefront of the development of the continuous bioprocessing. We are in the processing of building a cGMP plant that would have a fully integrated continuous bioprocess. We have already complete a proof of concept studies in pilot scale (50L)
  • Preview of USP’s Informational Chapter , Guidelines on the Endotoxins Test
    Preview of USP’s Informational Chapter , Guidelines on the Endotoxins Test Karen Zink McCullough of MMI Associates & Kevin L. Williams of BioMérieux Recorded: Jun 11 2018 61 mins
    Title: Preview of USP’s Informational Chapter, Guidelines on the Endotoxins Test
    Presenter: Karen Zink McCullough, MMI Associates
    The retirement of FDA’s 1987 Guideline on LAL testing left a number of gaps in the written body of knowledge
    on LAL testing. Some of these gaps include: Guidance on RSE:CSE standardization, Guidance on Training,
    Guidance on OOS test results, and Calculation of Endotoxin Limits. The proposed chapter, that will appear in the
    July/August issue of Pharmacopeial Forum, provides information and recommendations on these topics and
    more. This Webinar will provide an overview of the contents of this new informational chapter.

    Title: Regulatory Compliance of Alternative Methods
    Presenter: Kevin L. Williams, BIOMÉRIEUX
    Recombinant Horseshoe Crab Factor C (rFC) tests are endotoxin-specific alternatives to Limulus Amebocyte Lyste
    (LAL). The United States Food and Drug Administration included rFC in their Guidance for Industry in 2012 and in
    2016 the European Pharmacopoeia followed suit. Recently, the Japanese Pharmaceutical and Medical Device
    Agency published a collaborative study demonstrating equivalence between rFC and LAL. This presentation will
    provide an overview of how alternative method validation of rFC methods is conducted in accordance to USP
    chapters < 1225 > and < 85 >.
  • Calls for Papers Tutorial
    Calls for Papers Tutorial Kathleen Berryman Recorded: Jun 10 2018 2 mins
    A short tutorial showing the calls for papers feature in Cabells Whitelist
  • Cabells Metrics Tutorial
    Cabells Metrics Tutorial Kathleen Berryman Recorded: Jun 10 2018 6 mins
    A short tutorial on what metrics Cabells offers and what each one means.
  • Search and Advanced Search Tutorial
    Search and Advanced Search Tutorial Kathleen Berryman Recorded: Jun 10 2018 6 mins
    A short tutorial on how to use the search and advanced search features in Cabells.
  • More on the Unique Selectivity of Ionic Liquid GC Stationary Phases
    More on the Unique Selectivity of Ionic Liquid GC Stationary Phases Len Sidisky Recorded: Jun 7 2018 55 mins
    Over the years, extensive evaluations of columns manufactured with ionic liquid stationary phases have occurred. Their main strength was discovered to be unique selectivity. This selectivity is made possible due to the various combinations of cations and anions that are available along with spacer groups used to prepare these germinal
    dicationic phases. Columns prepared with di- or tricationic phases have the ability to perform many of the same applications as columns made with polysiloxane polymer or polyethylene glycol stationary phases of similar polarity, but with slight elution order changes. Many times this results in increased resolution and/or shorter run times. This webinar will compare and contrast the selectivity of the ionic liquids stationary phases with
    traditional phases of similar or like selectivity’s for applications with a
    variety of different sample types from a number of industries including
    petrochemical, pharmaceutical, environmental, food and beverage and flavor and fragrance.
  • Cryogenic Safety
    Cryogenic Safety Robert Done - Project design engineer - STFC - Rutherford Appleton Laboratory Jul 23 2018 1:00 pm UTC 60 mins
    An introductory guide to the health and safety considerations required when using cryogenic equipment. The presentation will be based on the recently published fifth edition of the BCC cryogenic safety manual, will look at the legislation in place, and highlight some of the more significant hazards associated with cryogenics. The underlying theme will be a focus on reducing risks.
  • HPLC Method Development in One and a Half Days Using the Selectivity Concept
    HPLC Method Development in One and a Half Days Using the Selectivity Concept Dr. Frank Michel, Analytical & Chromatography Scientific Advisor, Merck KGaA, Darmstadt, Germany Jul 24 2018 6:00 am UTC 75 mins
    Modern HPLC technologies such as UHPLC, monolithic silica or Fused-Core™ particles provide superior separation efficiency and resolution of peaks. But in general resolution is more strongly impacted by selectivity which in turn can be affected by different stationary bonded phases. This presentation will discuss the choice of RP HPLC column chemistries such as RP-Amide, Phenyl, Pentafluorophenyl (F5) or Cyano which can provide alternative selectivities to traditional C18. It will compare their different retention mechanisms and highlight an approach to develop HPLC method within one and a half days.
  • High-Throughput Microfluidic Platform for Culture of 3D-Kidney Tissue Models
    High-Throughput Microfluidic Platform for Culture of 3D-Kidney Tissue Models Henriëtte Lanz, Ph.D. Jul 24 2018 5:00 pm UTC 75 mins
    Drug toxicity remains a major issue in drug discovery and stresses the need for better predictive models. Here, we describe the development of a perfused renal proximal tubule cell (RPTC) model in Mimetas’ OrganoPlates® to predict kidney toxicity. The OrganoPlate® is a microfluidic platform, which enables high-throughput culture of boundary tissues in miniaturized organ models. In OrganoPlates®, ECM gels can be freely patterned in microchambers through the use of PhaseGuide technology. PhaseGuides define channels within microchambers that can be used for ECM deposition or medium perfusion. The microfluidic channel dimensions not only allow solid tissue and barrier formation, but also perfused tubular epithelial vessel structures can be grown. The goal of developing a perfused RPTC model is to reconstruct viable and leak-tight boundaries for performing cytotoxicity, as well as transport and efficacy studies. Human RPTC (SA7K clone, Sigma) were grown against an ECM in a 3channel OrganoPlate®, yielding access to both the apical and basal side. Confocal imaging revealed that the cells formed a tubular structure. Staining showed tight junction formations (ZO-1), cilia pointing into the lumen (acetylated tubulin) and correct polarization with microvilli on the apical side of the tubule (ezrin). Tightness of the boundary over several days was shown by diffusion of a dextran dye added to the lumen of the tubule. Addition of toxic compounds resulted in disruption of the barrier which could be monitored in time. The time point of loss of integrity corresponds with the concentration and the toxic effect of the compound. Furthermore, fluorescent transport assays showed functional transport activity of in- and efflux transporters. The 3D proximal tubules cultured in the OrganoPlate® are suitable for high-throughput toxicity screening, trans-epithelial transport studies, and complex co-culture models to recreate an in vivo-like microenvironment.
  • SUPERINSULATION – Heat Transfer and Influences on Insulation Performance
    SUPERINSULATION – Heat Transfer and Influences on Insulation Performance Holger Neumann – Divisional Head of Cryogenics of Institute for Technical Physics (ITEP) of KIT Jul 25 2018 1:00 pm UTC 60 mins
    1. Introduction with motivation to the best kind of insulation for cryogenic applications
    2. Heat transfer mechanisms
    3. Description of MLI
    4. Heat transfer calculation
    5. Special influences on insulation performance like contact pressure, layer density, T-junctions
    6. Examples
  • How to create a 5-year M&A plan for dealing with patent cliffs
    How to create a 5-year M&A plan for dealing with patent cliffs Jurgen Vollrath, President at Exponential Technology Counsel Jul 25 2018 3:00 pm UTC 60 mins
    A ‘Patent cliff’ describes a severe drop in revenue once the patent for a company’s leading product expires. The sharp revenue decline is a result of competitors being able to start developing and selling the product, often at a much lower price.

    As US biopharmaceutical company Celgene struggles to get regulatory approval from the FDA, the company is facing major market, shares and revenue losses, and is facing a phenomenal patent cliff. Furthermore, research from EvaluatePharma reports that an estimated $250 billion in projected sales is at risk between 2018-2024 as many drugs lose exclusivity.

    When it comes to acquisitions, the effects of a dwindling patent term can severely impact the value of your company. So how do you create 5-year plan to prepare for an inevitable patent cliff? We are very excited to welcome back Jurgen Vollrath, President of Exponential Technology Counsel, and customer of PatSnap. ET Counsel, advise clients on IP strategy & business alignment to ensure the most successful M&A and exit outcomes.

    In this webinar, Jurgen will be discussing:

    - Risk vs. reality when it comes to patent cliffs
    - How to create a 5-year M&A plan for your organisation
    - How to find potential acquisition targets
    - Predicting the potential impact a patent cliff could have on your business.
  • Subvisible Particles Matter, Developments in Regulations and Low Volume Methods
    Subvisible Particles Matter, Developments in Regulations and Low Volume Methods Dr Satish K Singh, Lonza Jul 26 2018 2:00 pm UTC 75 mins
    The need to measure and characterize proteinaceous particles in therapeutic protein products has been emphasized by regulators. USP is a new chapter that addresses the limitations of USP for therapeutic proteins in measurement of subvisible particles. USP is a guidance chapter addressing the task of characterization of particles with the emphasis on proteinaceous particles. Furthermore, regulatory authorities require that sponsors understand the submicron particle size range of the products also. This article will look at latest regulatory developments, key aspects of the measurement of subvisible and submicron particles in biotherapeutics, as well as the utility of low volume methods.
  • MR Image Guidance & On-Table Adaptive Radiotherapy in Routine Clinical Practice
    MR Image Guidance & On-Table Adaptive Radiotherapy in Routine Clinical Practice Miguel A. Palacios, Medical Physicist at VU Medical Centre and Lauren Henke, Radiation Oncologist at Washington University Jul 26 2018 3:00 pm UTC 60 mins
    Learn about the rationale and workflow for modifying radiation therapy treatments while the patient is on the table using Real-time On-table Adaptive Radiotherapy. Clinicians from hospitals in Amsterdam and St. Louis, MO will discuss their methodologies and clinical outcomes with the MRIdian® Linac system.

    MRI-Guided ROAR™ - Real-time On-table Adaptive Radiotherapy represents a new paradigm in the treatment of cancer, providing clinicians with the ability to improve targeting precision and thus deliver higher, and potentially more effective, radiation doses.

    • Learn how clinicians are adapting the radiation dose in real-time and watching every change/motion near the tumour with high contrast, soft-tissue imaging
    • Understand the clinical workflow of real-time, on-table adaptive radiotherapy
    • Hear examples of how MR Image-Guided Radiotherapy allows for personalized radiation therapy treatments and opportunistic dose escalation or de-escalation to avoid toxicity
  • Applications of Cryogenics: Past, Present, Future
    Applications of Cryogenics: Past, Present, Future Jorge Pelegrín Mosquera – Research Fellow at University of Southampton Jul 27 2018 1:00 pm UTC 60 mins
    Air was first liquefied in 1877. Since then, the cooling power has been harnessed for many applications that have impacted science and society.

    In this webinar a review of the applications that cryogenics has enabled will be presented. From gas liquefaction to the use of cryocoolers in applications such as MRI scans, particle detectors, accelerators or fusion technology.

    Looking to the future of cryogenics, quantum-computing promises vastly increased computational power via the use of novel materials. Superconducting and cryogenic technologies offer cleaner, more efficient transport and power networks.
  • Next generation processes: What model works the best in Asia?
    Next generation processes: What model works the best in Asia? Ravishankar Kasturi, Reliance Life Sciences & Marc Bisschops, Director Continuous Bioprocessing - SLS Aug 9 2018 5:00 am UTC 75 mins
    Compare and contrast the available full scale processing technologies, and discover what works the best for manufacturing next generation therapeutic products in Asia.

    Biologics are complex and hard to make, which helps to explain why biotech manufacturing plants are huge and expensive to build. To be competitive, manufacturing must be efficient and cost-effective and should brainstorm economical ways to manufacture biologics.

    Biosimilars are a cost competitive market. Pricing may have a direct impact on market share, and return on investment. The market for biologics, including approved and in pipeline like ADCs, antibodies & antibody fragments present both tremendous opportunity and challenge. Challenges necessitates looking beyond the current platform philosophy for how to modify the process with a goal to increase overall productivity in a flexible manner.

    The current processing paradigm of large manufacturing facilities dedicated to single product production is no longer an effective approach for manufacturing next generation therapeutic products in Asia.

    Cost Effective Biosimilars Manufacturing may include
    Single-use technologies and continuous upstream processes have proven to be cost-efficient options
    Aspects of continuous manufacturing in both upstream and downstream manufacturing are being incorporated thereby increasing yields through a combination of longer production run times, more stable and higher secreting cell lines
    Technologies enabling high productivity, right-sized, small footprint, continuous, and automated operations are being evaluated.
    Adaptive control techniques are set to minimize development timelines and enhance process robustness
    Partnerships will continue to transform biosimilars industry. In order to gain access to developed markets, Indian biosimilar manufacturers are partnering with multiple local established manufacturers and big pharmaceutical companies
  • IOP ebooks - Meet the author Professor Brian Diffey
    IOP ebooks - Meet the author Professor Brian Diffey Professor Brian Diffey Aug 9 2018 2:00 pm UTC 45 mins
    Join us for this 45 minute webinar with the author of Sun Protection: A risk management approach, Professor Brian Diffey. Professor Diffey will give an overview of his book, key learning points and answer your questions in a live Q&A.

    About the book
    Sun Protection differentiates itself from other texts by adopting a risk-management approach to determine whether, how, and in what circumstances, harm might be caused, and to explore the feasibility of various strategies in controlling exposure to solar UV radiation. This multi-disciplinary book covers topics from climatology through human exposure to sunlight, as well as biological and clinical effects of UV radiation to physical and chemical strategies for photoprotection.

    This webinar is recommended viewing for biologists and dermatologists and will be of interest to physical scientists and those working in the skin care industry.
  • The Impact of Artificial Intelligence in Medical Imaging
    The Impact of Artificial Intelligence in Medical Imaging Nadim Daher,Industry Principal, Siddharth Shah, Industry Analyst, Frost & Sullivan Aug 9 2018 3:00 pm UTC 60 mins
    Medical imaging has become a leader for the application of artificial intelligence technologies in the healthcare space, especially recently with deep learning techniques. This is evident from the fact that over 90 companies have set out to develop and commercialize AI-based solutions for the medical imaging industry. The number continues to grow as new start-ups emerge, as incumbents develop native AI solutions, and as tech companies move into the field, creating a highly dynamic ecosystem. With various countries edging past the innovator adoption phase and into the early adopter one, the time is now for stakeholders to refine and test their value proposition, partnership approach, and go-to-market strategies.

    Key Takeaways:
    • How far we have reached over the past five years and the current lay of the land
    • Where we are headed over the next five years and the direction of industry progress
    • Deep-dive into the opportunity for automation, acceleration and augmentation of medical image analysis
    • Anticipate the advent of intelligent medical imaging machines with embedded AI
  • Mixed mode Chromatography in Purifying biologics - Overview
    Mixed mode Chromatography in Purifying biologics - Overview Vivek Halan Zumutor Biologics Pvt Ltd, Bangalore, India Aug 13 2018 9:30 am UTC 75 mins
    This Webinar will discuss MMC in purifying biologics which includes monoclonal antibodies (mAbs), Bispecific antibodies (BsAbs), antibody fragments (Scfv,Fab) and other recombinant proåteins. My discussion is intended for audience from biopharmaceutical industry as well as active collaborators from academic institutes.
  • Is India Anywhere Closer to Implementing Continuous Bioprocessing
    Is India Anywhere Closer to Implementing Continuous Bioprocessing Narasimha Rao Nedunuri, CEO of CLONZ Biotech, and José Castillo, PhD, CTo and co-founder of Univercells Aug 16 2018 9:30 am UTC 75 mins
    Continuous processing has been widely employed in many biological manufacturing processes. In recent years it gained the momentum in the field of Biosimilar manufacturing due to an ever-increasing pressure for reduction in manufacturing costs.
    Potentially, the continuous processing offers Lower Cost of Goods, ease of scalability, and lower manufacturing footprint and hence became a topic of interest to many biosimilar players. Ongoing research on various new technologies for continuous operation, both in upstream and downstream processing may potentially be a game changer. Top on the wish list being, integration of all the multiple unit operations into a single continuous process with real time analytical tools.
    Though there are several challenges to develop and adapt continuous bioprocess, the magnitude of potential benefits are currently driving the research programs worldwide. India , being a significant global player in the biosimilar domain, currently making efforts to adapt these novel processes to make the drugs more cost effective.
  • Implementing CMC Strategies for scale-up operations in biologics manufacturing
    Implementing CMC Strategies for scale-up operations in biologics manufacturing Dr Anita Krishnan, Lupinand -Dr. Annu Uppal, Global Demo Lead and Advanced Workflow Specialist at SCIEX Aug 20 2018 9:30 am UTC 75 mins
    Biotechnological products are so complex, that manufacturing biologics which are both cost-effective and with best product quality, is a technical challenge. In the context of biosimilar manufacturing at each step, the sponsor should evaluate the extent to which there is residual uncertainty about the biosimilarity of the proposed product. Often there is remnant quality difference beyond the capability of process to address. In such instances, in-depth understanding of the process, impurities, analytical methods, the mechanism of action (MOA) of the drug substance and clinical relevance of any observed structural differences, will help in implementing novel CMC strategies. This talk will examine the elements of biopharmaceutical development that lead to successful licensure of biotherapeutics.
  • Material Understanding for Continuous Manufacturing of Solid Dosage Forms
    Material Understanding for Continuous Manufacturing of Solid Dosage Forms Dr Yifan Wang, regulatory research scientist, FDA CDER and -Dirk Leister, Head of the Application team Thermo Fisher Scienti Aug 23 2018 2:00 pm UTC 75 mins
    In continuous manufacturing of solid dosage forms, continued assurance of process performance and product quality is based on accurate and consistent flow of solid materials. Acknowledging the multidimensionality of material flow properties is often the first step to explore the material knowledge space. In addition, modular operations such as feeding and continuous blending often requires additional material testing for better understanding of process dynamics. As a key element of control strategy, tolerance of incoming material variations needs to be considered. The FDA’s Division of Pharmaceutical Quality Research is working to understand the impact of material properties and explore the material knowledge space for continuous manufacturing of solid dosage forms.
  • Project and Portfolio Management as a key tool to manage continuous improvement
    Project and Portfolio Management as a key tool to manage continuous improvement Gloria Gadea-Lopez, Ph.D.and Melvin Santos Sep 6 2018 2:00 pm UTC 75 mins
    Continuous improvement, risk mitigation and adherence to compliance rely on the successful execution of key initiatives aligned with an organization’s strategic imperatives. This article summarizes the Project and Portfolio initiatives at Shire’s Biologics manufacturing facility at Shire, Lexington, MA site. In addition to practical advice, the authors discuss the need for sound business processes, alignment with Finance and budget cycles, and play special attention to the importance of resource allocation and management.
  • Efficiency by Design- Case Study for a Hybrid Clinical Manufacturing Facility
    Efficiency by Design- Case Study for a Hybrid Clinical Manufacturing Facility Dr Sourav Kundu, Senior Director at Teva Pharmaceuticals Global Biologics R&D Sep 12 2018 2:00 pm UTC 75 mins
    Salient facility design aspects to achieve manufacturing efficiency
    Combining single use and stainless steel strategically creating a hybrid
    Risk-based approach to CQV- Reducing cost and tme
  • DSF and FTIR as methods for the identification and characterization
    DSF and FTIR as methods for the identification and characterization Marina Kirkitadze , Deputy Director, Head of Biophysics & Conformation Unit, Analytical R&D Biochemist & Kristen Kalbfleisch Sep 18 2018 2:00 pm UTC 75 mins
    The focus of this presentation is the application of Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Fluorimetry (DSF) methods to characterize vaccine components and their stability. Additionally, FTIR can be applied for the identification of final vaccine products, and DSF can be used to distinguish different formulations of vaccine candidates. These methods, when used in conjuction, provide valuable information regarding characterization and stability in the final stages of vaccine manufacturing.
  • Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 1
    Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 1 Anthony Saporita, PhD Sep 26 2018 1:00 am UTC 75 mins
    Monitoring protein biomarkers in cerebrospinal fluid (CSF) of patients with Alzheimer’s Disease (AD) has been highly beneficial to understanding disease progression.  While several CSF biomarkers can reproducibly distinguish normal and diseased samples, CSF is a difficult biological fluid to obtain in research studies.  The need for blood-based biomarkers of AD has driven a continuous search for novel candidates.  Here we report the development of a multiplex immunoassay to quantitatively measure seven proteins present in both CSF and blood that are involved in neurological disease:  Neurogranin, TREM2, ApoE4, FABP3, Ferritin, angiogenin, and prion protein.  Notably, presence of the APOE4 allele is prominently associated with an increased risk for AD, in comparison to the APOE2 and APOE3 alleles.  Although these ApoE isoforms differ at only one or two amino acids, our assay distinguished ApoE4 with minimal cross-reactivity. Using this novel immunoassay, we measured these 7 biomarkers in CSF, plasma, and serum from AD patients and healthy controls.  Additionally, we developed an ultrasensitive Single Molecule Counting (SMCTM) assay for amyloid beta 1-42 (Aβ42).  This kit could detect the Aβ42 peptide in CSF and plasma at sub-pg/mL concentrations.  This study demonstrates the value of evaluating both novel and established biomarkers of neurodegeneration across distinct sample types.
  • Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 2
    Multiplex immunoassay detection of Alzheimer’s disease biomarkers: Session 2 Anthony Saporita, PhD Sep 26 2018 3:00 pm UTC 75 mins
    Monitoring protein biomarkers in cerebrospinal fluid (CSF) of patients with Alzheimer’s Disease (AD) has been highly beneficial to understanding disease progression. While several CSF biomarkers can reproducibly distinguish normal and diseased samples, CSF is a difficult biological fluid to obtain in research studies. The need for blood-based biomarkers of AD has driven a continuous search for novel candidates. Here we report the development of a multiplex immunoassay to quantitatively measure seven proteins present in both CSF and blood that are involved in neurological disease: Neurogranin, TREM2, ApoE4, FABP3, Ferritin, angiogenin, and prion protein. Notably, presence of the APOE4 allele is prominently associated with an increased risk for AD, in comparison to the APOE2 and APOE3 alleles. Although these ApoE isoforms differ at only one or two amino acids, our assay distinguished ApoE4 with minimal cross-reactivity. Using this novel immunoassay, we measured these 7 biomarkers in CSF, plasma, and serum from AD patients and healthy controls. Additionally, we developed an ultrasensitive Single Molecule Counting (SMCTM) assay for amyloid beta 1-42 (Aβ42). This kit could detect the Aβ42 peptide in CSF and plasma at sub-pg/mL concentrations. This study demonstrates the value of evaluating both novel and established biomarkers of neurodegeneration across distinct sample types.
  • Tracking technology trends to maximise commercialisation value
    Tracking technology trends to maximise commercialisation value Mireya McKee CEO of McKee Innovation Consulting Sep 26 2018 3:00 pm UTC 60 mins
    Technology commercialisation at its core requires for an invention to be applied to a use case in a specific market. Doing this successfully will ensure that you are getting ROI out of your research and inventions. Mireya McKee has over 16 years experience in research, academia and commercialisation and will be talking about how she utilises technology trends to maximise commercialisation value.

    Some of the topics discussed in this webinar will be:

    * How to track technology trends
    * What can patents tell us about technology trends
    * Technology adoption cycle
    * How technology readiness levels can affect commercialisation opportunities
  • Overview of Certification Procedures for Organic Certified Reference Materials
    Overview of Certification Procedures for Organic Certified Reference Materials Ingrid Hayenga, PhD & Markus Obkircher, PhD Sep 27 2018 6:00 am UTC 75 mins
    his webinar highlights the different certification procedures regarding organic standards.

    Certified reference materials (CRMs) are an important and essential part of quality assurance. Laboratories accredited according to ISO 17025 must use CRMs on a regular base to prove their quality.

    For organic compounds, only a very limited number of CRMs from metrological institutes are available, due to this the big challenge is traceability.


    In this webinar, you will learn:
    •The certification process of the organic standard solutions by qNMR from the point of view of a commercial producer of certified reference materials under ISO/IEC 17025 and ISO 17034 accreditation.
  • Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Incre
    Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Incre Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis Sep 27 2018 8:00 am UTC 75 mins
    Title: Developability Assessment of Therapeutic Proteins – A Toolbox for Tackling Increasing Complexity
    Presenter: Thorsten Lorenz, Team Head Developability Assessment Biologics, Novartis

    Early lead selection of biotherapeutics during preclinical development requires careful characterization of a variety of molecule properties to reduce the risk for encountering unexpected obstacles during technical development. The diversity and increasing complexity of new protein formats requires a change from former platform approaches often applied for antibodies, to project specific strategies. The developability assessment concept applied at Novartis combines information addressing various technical areas, such as expression, aggregation propensity, process fit, stability, physicochemical properties, etc. This integrated concept prior to lead selection provides a thorough, yet resource efficient approach to select suitable candidates.
  • Overview of Certification Procedures for Organic Certified Reference Materials
    Overview of Certification Procedures for Organic Certified Reference Materials Ingrid Hayenga, PhD & Markus Obkircher, PhD Sep 27 2018 2:00 pm UTC 75 mins
    This webinar highlights the different certification procedures regarding organic standards.

    Certified reference materials (CRMs) are an important and essential part of quality assurance. Laboratories accredited according to ISO 17025 must use CRMs on a regular base to prove their quality.

    For organic compounds, only a very limited number of CRMs from metrological institutes are available, due to this the big challenge is traceability.


    In this webinar, you will learn:
    •The certification process of the organic standard solutions by qNMR from the point of view of a commercial producer of certified reference materials under ISO/IEC 17025 and ISO 17034 accreditation.